Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Sagimet Biosciences Inc.NASDAQ: SGMT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $10.65M (cash outflow) fell 41.4% year over year, behind the -23.8% change in trailing-twelve-month net income. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at +18.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$38.99M (-23.6%) for the fiscal year ending Dec 2026, a slowdown from the +12.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.65M+11.3% QoQ
- Last fiscal yearDec 2025
- -$51.04M+12.0% YoY
- LTMMar 2026
- -$43.51M-23.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -41.4% | +28.4% | +69.8 pp |
| 1 year | +12.0% | -23.6% | -35.6 pp |
| 3-year CAGR | +18.7% | +2.0% | -16.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (51.04M) USD
- Year-over-year change
- -12.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (51.04M) | -12.0% |
| FY2024 | 2024-12-31 | (45.57M) | -63.5% |
| FY2023 | 2023-12-31 | (27.88M) | +8.6% |
| FY2022 | 2022-12-31 | (30.5M) | -24.8% |
| FY2021 | 2021-12-31 | (24.44M) | — |
Net Income vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 net income of $43.51M is the 10th largest of the 11 companies compared; the peer median is $78.05M.
- Its year-over-year change of -23.8% is the 9th highest of 11, against a peer median of +14.0%.
- Over three fiscal years its annual growth of +18.7% compares with a peer median of +11.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $78.67M | +15.4% | — | 173.5% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Mar 2026 | $51.99M | +12.6% | +8.9% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $43.51M | -23.8% | +18.7% | — |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding SGMT) | $78.05M | +14.0% | +11.0% | 293.2% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.